SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development

References

• Chen J, Luo X, Qiu H, et al. Drug discovery and drug marketing with the critical roles of modern administration. Am J Transl Res. 2018;10(12):4302–4312.
   PubMed Web of Science ®Google Scholar
• Hughes JP, Rees S, Kalindjian SB, et al. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–1249.
   PubMed Web of Science ®Google Scholar
• Gashaw I, Ellinghaus P, Sommer A, et al. What makes a good drug target? Drug Discov Today. 2011;16(23–24):1037–1043.
   PubMed Web of Science ®Google Scholar
• Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16(1):19–34.
   PubMed Web of Science ®Google Scholar
• Lin Y, Mehta S, Küçük-mcginty H, et al. Drug target ontology to classify and integrate drug discovery data. J Biomed Semantics. 2017;8(1):50.
   PubMedGoogle Scholar
• Schenone M, Dančík V, Wagner BK, et al. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013;9(4):232–240.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma A, Sharma G, et al. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020;24(7):4016–4026.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A zoonotic prospective. Asian Pac J Trop Med. 2020;13(6):242–246.
   Web of Science ®Google Scholar
• Gandhi RT, Lynch JB, Del rio C. Mild or moderate COVID-19. N Engl J Med. 2020;383(18):1757–1766.
   PubMed Web of Science ®Google Scholar
• Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–677.
   PubMed Web of Science ®Google Scholar
• Saha A, Sharma AR, Bhattacharya M, et al. Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in COVID-19. Arch Med Res. 2020;51(6):595–597.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, et al. COVID‐19: consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients. J Med Virol. 2020;92(11):2260–2262.
   PubMed Web of Science ®Google Scholar
• Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506–510.
   PubMed Web of Science ®Google Scholar
• Yang S, Cao P, Du P, et al. Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis. Ann Transl Med. 2020;8(4):128.
   PubMed Web of Science ®Google Scholar
• Saha A, Sharma AR, Bhattacharya M, et al. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Arch Med Res. 2020;51(6):585–586.
   PubMed Web of Science ®Google Scholar
• Saha RP, Singh MK, Samanta S, et al. Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19. Front Pharmacol. 2020;11:1258.
   PubMed Web of Science ®Google Scholar
• Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMR-based screening data. J Med Chem. 2005;48(7):2518–2525.
   PubMed Web of Science ®Google Scholar
• Keller TH, Pichota A, Yin Z. A practical view of ‘druggability’. Curr Opin Chem Biol. 2006;10(4):357–361.
   PubMed Web of Science ®Google Scholar
• Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006;5(10):821–834.
   PubMed Web of Science ®Google Scholar
• Zheng C, Han L, Yap C, et al. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev. 2006;58(2):259–279.
   PubMed Web of Science ®Google Scholar
• Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today. 2005;10(23–24):1607–1610.
   PubMed Web of Science ®Google Scholar
• Mitsopoulos C, Schierz AC, Workman P, et al. Distinctive behaviors of druggable proteins in cellular networks. PLoS Comput Biol. 2015;11(12):e1004597.
   PubMed Web of Science ®Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–996.
   PubMed Web of Science ®Google Scholar
• Bakheet TM, Doig AJ. Properties and identification of human protein drug targets. Bioinformatics. 2009;25(4):451–457.
   PubMed Web of Science ®Google Scholar
• Vinayagam A, Gibson TE, Lee H-J, et al. Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets. Proc Natl Acad Sci U S A. 2016;113(18):4976–4981.
   PubMed Web of Science ®Google Scholar
• Chakraborty C. George Priya Doss C. Crucial protein based drug targets and potential inhibitors for osteoporosis: new hope and possibilities. Curr Drug Targets. 2013;14(14):1707–1713.
   PubMed Web of Science ®Google Scholar
• Mohamed SK, Nováček V, Nounu A. Discovering protein drug targets using knowledge graph embeddings. Bioinformatics. 2020;36(2):603–610.
   PubMed Web of Science ®Google Scholar
• Shyr ZA, Gorshkov K, Chen CZ, et al. Drug discovery strategies for SARS-CoV-2. J Pharmacol Exp Ther. 2020;375(1):127–138.
   PubMed Web of Science ®Google Scholar
• Senanayake SL. Drug repurposing strategies for COVID-19. Future Drug Discov. 2020;2(2). DOI:10.4155/fdd-2020-0010
   Google Scholar
• Saxena A. Drug targets for COVID-19 therapeutics: ongoing global efforts. J Biosci. 2020;45(1):1–24.
   PubMed Web of Science ®Google Scholar
• Ghahremanpour MM, Tirado-Rives J, Deshmukh M, et al. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med Chem Lett. 2020;11(12):2526–2533.
   PubMed Web of Science ®Google Scholar
• Zhu W, Xu M, Chen CZ, et al. Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening. ACS Pharmacol Transl Sci. 2020;3(5):1008–1016.
   PubMedGoogle Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150.
   PubMed Web of Science ®Google Scholar
• Bello M, Martínez-muñoz A, Balbuena-rebolledo I. Identification of saquinavir as a potent inhibitor of dimeric sars-cov2 main protease through mm/gbsa. J Mol Model. 2020;26(12):1.
   Web of Science ®Google Scholar
• Pattnaik GP, Chakraborty H. Entry inhibitors: efficient means to block viral infection. J Membr Biol. 2020;253(5):425–444.
   PubMed Web of Science ®Google Scholar
• Cannalire R, Stefanelli I, Cerchia C, et al. SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells. Int J Mol Sci. 2020;21(16):5707.
   Web of Science ®Google Scholar
• Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-ncov) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343–355.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang C, Xu X-F, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for covid-19.acta. Pharmacol Sin. 2020;41(9):1141–1149.
   PubMed Web of Science ®Google Scholar
• Huang J, Huang H, Wang D, et al. Immunological strategies against spike protein: neutralizing antibodies and vaccine development for COVID-19. Clin Transl Med. 2020;10(6):e184.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020;16(6):1232–1238.
   PubMed Web of Science ®Google Scholar
• Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707.
   PubMed Web of Science ®Google Scholar
• Mahendran ASK, Lim YS, Fang C-M, et al. The potential of antiviral peptides as COVID-19 therapeutics. Front Pharmacol. 2020;11:1475.
   Web of Science ®Google Scholar
• VanPatten S, He M, Altiti A, et al. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. Future Med Chem. 2020;12(18):1647–1656.
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727–11734.
   PubMed Web of Science ®Google Scholar
• Xiu S, Dick A, Ju H, et al. Inhibitors of SARS-CoV-2 entry: current and future opportunities. J Med Chem. 2020;63(21):12256–12274.
   PubMed Web of Science ®Google Scholar
• Saponaro F, Rutigliano G, Sestito S, et al. Ace2 in the era of SARS-CoV-2: controversies and novel perspectives. Front Mol Biosci. 2020;7:588618.
   PubMed Web of Science ®Google Scholar
• Kawase M, Shirato K, van der hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86(12):6537–6545.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Tiwari V, Beer JC, Sankaranarayanan NV, et al. Discovering small-molecule therapeutics against SARS-CoV-2. Drug Discov Today. 2020;25(8):1535–1544.
   PubMed Web of Science ®Google Scholar
• Breining P, Frølund AL, Højen JF, et al. Camostat mesylate against sars‐cov‐2 and COVID‐19–rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2020. DOI:10.1111/bcpt.13533
   PubMed Web of Science ®Google Scholar
• Saha A, Sharma AR, Bhattacharya M, et al. Response to: status of remdesivir: not yet beyond question! arch med res. 2020; S0188-4409(20)31686-6.
   Google Scholar
• Gil ayuso-gontán C, Ginex T, Maestro I, et al. COVID-19: drug targets and potential treatments. J Med Chem. 2020;63(21):12359–12386.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 Jun01;582(7811):289–293.
   PubMed Web of Science ®Google Scholar
• Ton A-T, Gentile F, Hsing M, et al. Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol Inform. 2020;39(8):2000028.
   PubMed Web of Science ®Google Scholar
• Wang L, Bao -B-B, Song G-Q, et al. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of sars-cov main protease: chemical synthesis, biological evaluation, molecular docking and 3d-qsar study. Eur J Med Chem. 2017;137:450–461.
   PubMed Web of Science ®Google Scholar
• Ratia K, Saikatendu KS, Santarsiero BD, et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci U S A. 2006;103(15):5717–5722.
   PubMed Web of Science ®Google Scholar
• Klemm T, Ebert G, Calleja DJ, et al. Mechanism and inhibition of the papain‐like protease, plpro, of sars‐cov‐2. Embo J. 2020;39(18):e106275.
   PubMed Web of Science ®Google Scholar
• Thiel V, Ivanov KA, Putics A, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol. 2003;84(9):2305–2315.
   PubMedGoogle Scholar
• Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165878.
   PubMed Web of Science ®Google Scholar
• Joshi RS, Jagdale SS, Bansode SB, et al. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. J Biomol Struct Dyn. 2020;1–16. DOI:10.1080/07391102.2020.1760137.
   Web of Science ®Google Scholar
• Zhang L, Lin D, Sun X, et al. Crystal structure of sars-cov-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368(6489):409–412.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of m pro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–788.
   PubMed Web of Science ®Google Scholar
• Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A. 2003;100(23):13190–13195.
   PubMed Web of Science ®Google Scholar
• Ul qamar MT, Alqahtani SM, Alamri MA, et al. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10(4):313–319.
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763–1767.
   PubMed Web of Science ®Google Scholar
• Anand K, Palm GJ, Mesters JR, et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α‐helical domain. Embo J. 2002;21(13):3213–3224.
   PubMed Web of Science ®Google Scholar
• Dai W, Zhang B, Jiang X-M, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331–1335.
   PubMed Web of Science ®Google Scholar
• Vuong W, Khan MB, Fischer C, et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2020;11(1):4282.
   PubMed Web of Science ®Google Scholar
• Ma C, Sacco MD, Hurst B, et al. Boceprevir, gc-376, and calpain inhibitors ii, xii inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;(8):678–692.
   Google Scholar
• Ma C, Hu Y, Townsend JA, et al. Ebselen, disulfiram, carmofur, px-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol Transl Sci. 2020;3(6):1265–1277.
   PubMedGoogle Scholar
• Bello M, Martínez-muñoz A, Balbuena-rebolledo I. Identification of saquinavir as a potent inhibitor of dimeric sars-cov2 main protease through mm/gbsa. J Mol Model. 2020;26(12):340.
   PubMed Web of Science ®Google Scholar
• Martiniano B. Prediction of potential inhibitors of the dimeric sars-cov2 main proteinase through the mm/gbsa approach. J Mol Graph Model. 2020. DOI:10.1016/j.jmgm.2020.107762
   Web of Science ®Google Scholar
• Harcourt BH, Jukneliene D, Kanjanahaluethai A, et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol. 2004;78(24):13600–13612.
   PubMed Web of Science ®Google Scholar
• Gao X, Qin B, Chen P, et al. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B. 2020. DOI:10.1016/j.apsb.2020.08.014.
   Web of Science ®Google Scholar
• Krishna SS, Majumdar I, Grishin NV. Survey and summary: structural classification of zinc fingers. Nucleic Acids Res. 2003;31(2):532–550.
   PubMed Web of Science ®Google Scholar
• Gao X, Qin B, Chen P, et al. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B. 2020. DOI:10.1016/j.apsb.2020.08.014
   Web of Science ®Google Scholar
• Machitani M, Yasukawa M, Nakashima J, et al. RNA-dependent RNA polymerase, rdrp, a promising therapeutic target for cancer and potentially covid‐19. Cancer Sci. 2020;111(11):3976–3984.
   PubMed Web of Science ®Google Scholar
• McDonald SM. RNA synthetic mechanisms employed by diverse families of rna viruses. Wiley Interdiscip Rev RNA. 2013;4(4):351–367.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368(6492):779–782.
   PubMed Web of Science ®Google Scholar
• Moustafa IM, Shen H, Morton B, et al. Molecular dynamics simulations of viral RNA polymerases link conserved and correlated motions of functional elements to fidelity. J Mol Biol. 2020;410(1):159–181.
   Google Scholar
• Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the rna-dependent rna polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368(6498):1499–1504.
   PubMed Web of Science ®Google Scholar
• Nejadi babadaei MM, Hasan A, Vahdani Y, et al. Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. J Biomol Struct Dyn. 2020. DOI:10.1080/07391102.2020.1767210
   Web of Science ®Google Scholar
• Wang Y, Anirudhan V, Du R, et al. RNA-dependent RNA polymerase of sars‐cov‐2 as a therapeutic target. J Med Virol. 2020. DOI:10.1002/jmv.26264
   Web of Science ®Google Scholar
• Zhu W, CZ C, Gorshkov K, et al. RNA-dependent RNA polymerase as a target for COVID-19 drug discovery. SLAS Discov. 2020;25(10):1141–1151.
   PubMed Web of Science ®Google Scholar
• Elfiky AA. SARS-CoV-2 RNA-dependent RNA polymerase (rdrp) targeting: an in silico perspective. J Biomol Struct Dyn. 2020;1–9. DOI:10.1080/07391102.2020.1761882
   Web of Science ®Google Scholar
• Wakchaure PD, Ghosh S, Ganguly B. Revealing the inhibition mechanism of RNA-dependent RNA polymerase (rdrp) of SARS-CoV-2 by remdesivir and nucleotide analogues: a molecular dynamics simulation study. J Phys Chem B. 2020;124(47):10641–10652.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–6797.
   PubMed Web of Science ®Google Scholar
• Snijder E, Decroly E, Ziebuhr J. The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv Virus Res. 2016;96:59–126.
   PubMed Web of Science ®Google Scholar
• Romano M, Ruggiero A, Squeglia F, et al. A structural view of SARS-CoV-2 rna replication machinery: rna synthesis, proofreading and final capping. Cells. 2020;9(5):1267.
   PubMed Web of Science ®Google Scholar
• Jia Z, Yan L, Ren Z, et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus nsp13 upon atp hydrolysis. Nucleic Acids Res. 2019;47(12):6538–6550.
   PubMed Web of Science ®Google Scholar
• Chen J, Malone B, Llewellyn E, et al. Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. Cell. 2020;182(6):1560–1573.e13.
   PubMed Web of Science ®Google Scholar
• Ivanov KA, Ziebuhr J. Human coronavirus 229E nonstructural protein 13: characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5′-triphosphatase activities. J Virol. 2004;78(14):7833–7838.
   PubMed Web of Science ®Google Scholar
• Habtemariam S, Nabavi SF, Banach M, et al. Should we try SARS-CoV-2 helicase inhibitors for COVID-19 therapy? Arch Med Res. 2020;51(7):733–735.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220.
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Liu C, et al. Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry. PLoS Pathog. 2020;16(3):e1008392.
   PubMed Web of Science ®Google Scholar
• Saputri DS, Li S, Van eerden FJ, et al. Flexible, functional, and familiar: characteristics of SARS-CoV-2 spike protein evolution. Front Microbiol. 2020;11:2112.
   PubMed Web of Science ®Google Scholar
• Bhattacharya M, Sharma AR, Mallick B, et al. Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex. Infect Genet Evol. 2020;85:104587.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;;181(2):281–292.e6.
   PubMed Web of Science ®Google Scholar
• Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in wuhan, china: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020;9(1):275–277.
   PubMed Web of Science ®Google Scholar
• Singh B. Role of key point mutations in receptor binding domain of SARS-CoV-2 spike glycoprotein. Infect Disord Drug Targets. 2020;20. DOI:10.2174/1871526520666200804161650.
   Google Scholar
• Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448.
   PubMed Web of Science ®Google Scholar
• Yang J, Petitjean S, Derclaye S, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020;11(1):4541.
   PubMed Web of Science ®Google Scholar
• Mittal A, Manjunath K, Ranjan RK, et al. COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog. 2020;16(8):e1008762.
   PubMed Web of Science ®Google Scholar
• Jaimes J, Millet J, Whittaker G. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. iScience. 2020;23(6):101212.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76–84.
   PubMed Web of Science ®Google Scholar
• Ehmke V, Winkler E, Banner DW, et al. Optimization of triazine nitriles as rhodesain inhibitors: structure–activity relationships, bioisosteric imidazopyridine nitriles, and X‐ray crystal structure analysis with human cathepsin L. Chem Med Chem. 2013;8(6):967–975.
   Google Scholar
• Fujishima A, Imai Y, Nomura T, et al. The crystal structure of human cathepsin L complexed with E-64. FEBS Lett. 1997;407(1):47–50.
   PubMed Web of Science ®Google Scholar
• Yuan L, Zou C, Ge W, et al. A novel cathepsin L inhibitor prevents the progression of idiopathic pulmonary fibrosis. Bioorg Chem. 2020;94:103417.
   PubMed Web of Science ®Google Scholar
• Sacco MD, Ma C, Lagarias P, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against m pro and cathepsin l. Sci Adv. 2020;6(50):eabe0751.
   PubMed Web of Science ®Google Scholar
• Hu Y, Ma C, Szeto T, et al. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture. bioRxiv. 2020. DOI:10.1101/2020.10.30.362335
   Google Scholar
• Coutard B, Valle C, de lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-ncov contains a furin-like cleavage site absent in cov of the same clade. Antiviral Res. 2020;176:104742.
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134.
   PubMed Web of Science ®Google Scholar
• Henrich S, Cameron A, bourenkov GP, et al. Than ME The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Natur Struct Biol. 2003;10(7):520–526.
   PubMedGoogle Scholar
• Dahms SO, Arciniega M, Steinmetzer T, et al. Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. Proc Natl Acad Sci U S A. .2016;113(40):11196–11201.
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134.
   PubMed Web of Science ®Google Scholar
• Lukassen S, Chua RL, Trefzer T, et al. SARS‐CoV‐2 receptor ACE 2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. Embo J. 2020;39(10):e105114.
   PubMed Web of Science ®Google Scholar
• Sakai K, Ami Y, Tahara M, et al. The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses. J Virol. 2014;88(10):5608–5616.
   PubMed Web of Science ®Google Scholar
• Durdaği S. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target. Turk J Biol. 2020;44(3):185–191.
   PubMed Web of Science ®Google Scholar
• Huggins DJ. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2. J Mol Graph Model. 2020;100:107710.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-weber H, Schroeder S, et al. Müller ma. sars-cov-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):1–10.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Ohto-nakanishi T, et al. Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010;128(1):119–128.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):1–5.
   PubMed Web of Science ®Google Scholar
• Ren X, Glende J, Al-falah M, et al. Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus.J. Gen Virol. 2006;87(6):1691–1695.
   PubMedGoogle Scholar
• Towler P, Staker B, Prasad SG, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem. 2004;279(17):17996–18007.
   PubMed Web of Science ®Google Scholar
• Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and covid-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–435.
   PubMedGoogle Scholar
• Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):taaa041.
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Ribavirin R, Sofosbuvir G. Tenofovir against SARS-CoV-2 RNA-dependent RNA polymerase (rdrp): a molecular docking study. Life Sci. 2020;253:117592.
   PubMed Web of Science ®Google Scholar
• Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clin Pharmacol Ther 2020;108(2):242–247.
   PubMed Web of Science ®Google Scholar
• Tanner JA, Zheng B-J, Zhou J, et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol. 2005;12(3):303–311.
   PubMedGoogle Scholar
• Adedeji AO, Singh K, Calcaterra NE, et al. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother. 2012;56(9):4718–4728.
   PubMed Web of Science ®Google Scholar
• Adedeji AO, Severson W, Jonsson C, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013;87(14):8017–8028.
   PubMed Web of Science ®Google Scholar
• Barton C, Kouokam JC, Lasnik AB, et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014;58(1):120–127.
   PubMed Web of Science ®Google Scholar
• Dahms SO, Hardes K, Steinmetzer T, et al. X-ray structures of the proprotein convertase furin bound with substrate analogue inhibitors reveal substrate specificity determinants beyond the s4 pocket. Biochemistry. 2018;57(6):925–934.
   PubMed Web of Science ®Google Scholar
• Shen LW, Mao HJ, Wu YL, et al. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017;142:1–10.
   PubMed Web of Science ®Google Scholar
• Wang X, Dhindsa R, Povysil G, et al. Transcriptional inhibition of host viral entry proteins as a therapeutic strategy for SARS-CoV-2. Drug Dev Res. 2020. DOI:10.20944/preprints202003.0360.v1
   Google Scholar
• Rothlin RP, Vetulli HM, Duarte M, et al. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res. 2020;81(7):768–770.
   PubMed Web of Science ®Google Scholar